http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006004736-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d366b4ece0491dac1ec7d00c8b272e8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_185b7c4ad69cfeef09db04a529beaaf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5769cd4cd6c6ede932ce8abbdaa4d583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e70044ecc41c26ab59d4f769900b409d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b936f92017d116e0a74c90c71e1c6384
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbbd2ce1a6e52f56543bfdfe65afe55a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6a59d01502b499810010c88fec482c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5579039250b08ab323b71cf43c6c77da
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ba7946138b9146dbc2f1c7393e5f8ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43a73cdfab278763f101304774d6aba6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a2f250e60258a22836dd67c95382f51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1813ce82b3e52602ea3c75f48ceb90b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a05cfce7e1032b1814a732a3f13e2bbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f35bc1f942f61e48388fc4f1fdb8a44b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01182f4a9fdc7f76d71606379b3580bb
publicationDate 2007-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006004736-A3
titleOfInvention Stable liquid and lyophilized formulation of proteins
abstract The present invention is directed to stable protein derivatives, e.g., antibodies, antibody fragments or peptides, with at least one free thiol group coupled to N-acetyl-L-cysteine, N-ethyl-maleimide, or cysteine and the methods of making such derivatives. In addition, stable liquid pharmaceutical formulations comprising such proteins or their derivatives and stable lyophilized pharmaceutical formulations comprising such proteins are provided. The present invention is also directed to a method of making a stable Fab' fragment of an antibody and a method of controlling vascularization in injured or cancerous tissue comprising applying to the injured tissue one or more doses of the pharmaceutical formulations.
priorityDate 2004-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6210707-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003138417-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003040044-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9825971-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409359
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415847620
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID142751
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4362
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397808
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480290
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486540
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12035

Total number of triples: 71.